Physician profile
James Huddleston
NPI 1619037496
$1,520,882.83
in general payments reported to CMS, 2019-2025
8 companies · $623K in 2025
The $623K reported for 2025 was more than what 97% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139K · 2020: $55K · 2021: $340K · 2022: $133K · 2023: $97K · 2024: $135K · 2025: $623K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $552K · Royalty Or License: $285K · Travel and Lodging: $14K · Food and Beverage: $3,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $552,405.86 |
| Royalty Or License | $284,549.69 |
| Travel and Lodging | $14,374.86 |
| Food and Beverage | $3,167.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exactech, INC. | $693,748.44 | 2019-2025 | |
| Zimmer Biomet Holdings, INC. | $475,880.62 | 2019-2025 | Rosa |
| Depuy Synthes Products, INC. | $255,330.09 | 2021-2025 | Velys |
| Corin USA | $50,879.52 | 2019 | |
| Omnilife Science, INC | $36,958.53 | 2019-2022 | |
| Medical Device Business Services, INC. | $7,675.13 | 2021-2024 | |
| Smith+Nephew, INC. | $315.80 | 2024 | Real Intelligence, Journey II |
| Medtronic USA, INC. | $94.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,747,295.31 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Huddleston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.